N. Gabrail

R. Herbst, Z. Shun, V. Miller, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer

L. Carey, A. Bardia, K. Blackwell, 2018, Breast Cancer Research and Treatment.

Fentanyl pectin nasal spray for breakthrough cancer pain.

N. Gabrail, D. Taylor, 2012, Future oncology.

A multicenter, placebo-controlled, double-blind, multiple-crossover study of Fentanyl Pectin Nasal Spray (FPNS) in the treatment of breakthrough cancer pain

Allen W. Burton, Russell K. Portenoy, A. Burton, 2010, PAIN®.

Pulmonary hamartoma syndrome.

N. Gabrail, B. Zara, Barbara Y. Zara, 1990, Chest.

Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ASTX727 (cedazuridine/decitabine) Compared to IV Decitabine

H. Deeg, G. Garcia-Manero, K. Yee, 2019, Blood.

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

Angela G. Fleischman, A. Salar, S. Verstovsek, 2023, The Lancet.

Safety, Efficacy, and Determination of the Recommended Phase 2 Dose for the Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330)

Michael L. Wang, I. Flinn, R. Garzon, 2015 .

APF530 versus ondansetron, each in a guideline-recommended three-drug regimen, for the prevention of chemotherapy-induced nausea and vomiting due to anthracycline plus cyclophosphamide–based highly emetogenic chemotherapy regimens: a post hoc subgroup analysis of the Phase III randomized MAGIC trial

Michael C. Mosier, N. Vogelzang, N. Gabrail, 2017, Cancer management and research.

Liquid biopsy mutation panel for non-small cell lung cancer: analytical validation and clinical concordance

A. Bergamaschi, F. Baehner, C. Escriu, 2020, npj Precision Oncology.

Phase 3b UPFRONT Study: Safety and Efficacy of Weekly Bortezomib Maintenance Therapy After Bortezomib-Based Induction Regimens In Elderly, Newly Diagnosed Multiple Myeloma Patients

J. Reeves, I. Flinn, R. Neuwirth, 2010 .

Effect of the Cytochrome P450 2C19 Inhibitor Omeprazole on the Pharmacokinetics and Safety Profile of Bortezomib in Patients with Advanced Solid Tumours, Non-Hodgkin’s Lymphoma or Multiple Myeloma

J. Nemunaitis, C. Britten, D. Quinn, 2009, Clinical pharmacokinetics.

A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab

R. Vij, D. Atanackovic, P. Moreau, 2021, Blood Cancer Journal.

1083MO Final results from ILLUMINATE-204, a phase I/II trial of intratumoral tilsotolimod in combination with ipilimumab in PD-1 inhibitor refractory advanced melanoma

Douglas B. Johnson, I. Puzanov, J. Markowitz, 2020 .

Phase (Ph) 1 study of oral seviteronel (VT-464), a dual CYP17-Lyase (L) inhibitor and androgen receptor (AR) antagonist, in patients (pts) with advanced AR+ triple negative (TNBC) or estrogen receptor (ER)+ breast cancer (BC).

A. Bardia, T. Traina, M. Danso, 2016 .

Coexistence of essential thrombocythemia and chronic lymphocytic leukemia.

N. Gabrail, T. W. Martin, N. Gabrail, 1991, Acta haematologica.

Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial.

M. Kersten, M. Millenson, H. Tilly, 2018, The Lancet. Haematology.

Vaccination of castration-resistant prostate cancer patients with TroVax (MVA–5T4) in combination with docetaxel: a randomized phase II trial

S. Srinivas, N. Gabrail, A. Ferrari, 2013, Cancer Immunology, Immunotherapy.

TROPICS 1: a phase III, randomized, double-blind, placebo-controlled study of tenecteplase for restoration of function in dysfunctional central venous catheters.

M. Blaney, N. Gabrail, E. Sandler, 2010, Journal of vascular and interventional radiology : JVIR.

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carﬁlzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2012 .

Long-Term Follow Up Of a Randomized Phase II Study Of The JAK2-Selective Inhibitor Fedratinib (SAR302503) In Patients With Myelofibrosis (MF)

M. Talpaz, A. Tefferi, C. Jamieson, 2013 .

Phase 3b UPFRONT Study: Interim Results From a Community Practice-Based Prospective Randomized Trial Evaluating Three Bortezomib-Based Regimens in Elderly, Newly Diagnosed Multiple Myeloma Patients.

J. Reeves, I. Flinn, R. Neuwirth, 2009 .

Safety, Pharmacokinetics, and Activity of GRN1005, a Novel Conjugate of Angiopep-2, a Peptide Facilitating Brain Penetration, and Paclitaxel, in Patients with Advanced Solid Tumors

A. Brenner, R. Kurzrock, S. Moulder, 2011, Molecular Cancer Therapeutics.

Evaluation of CNS and peripheral antitumor activity of ANG1005 in patients with brain metastases from breast tumors and other advanced solid tumors.

S. Bates, S. Kesari, R. Kurzrock, 2014 .

Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors

D. Potvin, H. Hurwitz, E. Chan, 2018, Cancer Chemotherapy and Pharmacology.

Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial.

A. Dobs, J. Dalton, M. Steiner, 2013, The Lancet. Oncology.

Oral Decitabine/Cedazuridine in Patients with Lower Risk Myelodysplastic Syndrome: A Longer-Term Follow-up of from the Ascertain Study

B. Leber, H. Deeg, H. Kantarjian, 2021, Blood.

Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer.

C. Punt, J. Picus, M. Morse, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Real-world effectiveness of palonosetron-based antiemetic regimens: preventing chemotherapy-induced nausea and vomiting.

N. Gabrail, R. Geller, L. Schwartzberg, 2019, Journal of comparative effectiveness research.

Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double-blind, noninferiority phase 3 trial

R. Gralla, N. Gabrail, H. Raftopoulos, 2014, Supportive Care in Cancer.

Phase (Ph) 2 stage 1 clinical activity of seviteronel, a selective CYP17-lyase and androgen receptor (AR) inhibitor, in women with advanced AR+ triple-negative breast cancer (TNBC) or estrogen receptor (ER)+ BC: CLARITY-01.

A. Bardia, T. Traina, M. Danso, 2017 .

Treatment of chemotherapy-induced anemia in breast cancer: results of a randomized controlled trial of darbepoetin alfa 200 microg every 2 weeks versus epoetin alfa 40,000 U weekly.

N. Gabrail, L. Schwartzberg, D. Tomita, 2005, Clinical breast cancer.

Abstract B49: GRN1005 phase I studies: Final results.

T. Mikkelsen, P. Wen, S. Rosenfeld, 2011 .

Phase I, open-label, dose-escalation study of SNX-5422 plus everolimus in neuroendocrine tumors (NETs)

G. Giaccone, U. Guha, N. Gabrail, 2016 .

Phase 1/2 study of veliparib (V) combined with carboplatin (Cb) and etoposide (E) in patients (pts) with extensive-stage disease (ED) small cell lung cancer (SCLC) and other solid tumors: Phase 1 results.

H. Groen, L. Byers, D. Camidge, 2017 .

Phase II study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced non-small cell lung cancer (NSCLC)

N. Iannotti, N. Gabrail, A. Spira, 2007 .

Abstract P2-08-04: Phase 1/2 study of oral seviteronel (VT-464), a dual CYP17-lyase inhibitor and androgen receptor (AR) antagonist, in patients with advanced AR positive triple negative (TNBC) or estrogen receptor (ER) positive breast cancer (BC)

A. Bardia, M. Danso, A. Elias, 2017 .

Introduction: myeloproliferative disorders.

N. Gabrail, A. List, D. Doll, 1995, Seminars in oncology.

OP-106 Horizon — Melflufen Therapy for RRMM Patients Refractory to Daratumumab and/or Pomalidomide; Updated Results and First Report on PFS

P. Richardson, D. Chauhan, A. Oriol, 2018, Blood.

Melflufen Therapy for Relapsed Refractory Multiple Myeloma (RRMM) Patients Refractory to Daratumumab and/or Pomalidomide: A Report on Early Efficacy

P. Richardson, A. Oriol, A. Larocca, 2017 .

Phase Ib Multicenter Dose Escalation Study of Carfilzomib Plus Lenalidomide and Low Dose Dexamethasone (CRd) in Relapsed and Refractory Multiple Myeloma (MM).

R. Orlowski, N. Gabrail, W. Bensinger, 2009 .

Final Results From the Bortezomib-naïve Group of PX-171-004, a Phase 2 Study of Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory MM

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2011 .

ANG1005: Results of a phase I study in patients with advanced solid tumors and brain metastases.

A. Brenner, R. Kurzrock, S. Moulder, 2010 .

Interim results from a phase Ib/II study of pepinemab in combination with avelumab in advanced NSCLC patients following progression on prior systemic and/or anti-PDx therapies.

R. Govindan, A. Mansfield, Y. Lou, 2020, Journal of Clinical Oncology.

Real-world efficacy: intravenous palonosetron three-drug regimen for chemotherapy-induced nausea and vomiting with highly emetogenic chemotherapy.

N. Gabrail, R. Geller, T. Mclaughlin, 2018, Journal of comparative effectiveness research.

APF530 (granisetron injection extended-release) in a three-drug regimen for delayed CINV in highly emetogenic chemotherapy.

Michael C. Mosier, Robert E. Smith, N. Gabrail, 2016, Future oncology.

Prolonged Survival in Bi-Allelic TP53-Mutated (TP53mut) MDS Subjects Treated with Oral Decitabine/Cedazuridine in the Ascertain Trial (ASTX727-02)

B. Leber, G. Garcia-Manero, K. Yee, 2022, Blood.

Preliminary analysis of a U.S. phase II study of the safety and tolerability of proxalutamide (GT0918) in subjects with mCRPC who had progressed on either abiraterone (Abi) or enzalutamide (Enza).

A. Ross, N. Vogelzang, N. Gabrail, 2021 .

Selective HDAC6 Inhibitor ACY-241, an Oral Tablet, Combined with Pomalidomide and Dexamethasone: Safety and Efficacy of Escalation and Expansion Cohorts in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma (ACE-MM-200 Study)

J. Miguel, P. Richardson, N. Raje, 2016 .

A phase I/II study of MM-111, a novel bispecific antibody that targets the ErB2/ErB3 heterodimer, in combination with trastuzumab in advanced refractory HER2-positive breast cancer.

J. Murray, N. Gabrail, P. Ryan, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A multicenter, phase II study of CPX-1 liposome injection in patients (pts) with advanced colorectal cancer (CRC)

G. Batist, D. Spigel, N. Gabrail, 2008 .

A phase II study of eribulin mesylate (E7389) in patients with advanced, previously treated non-small-cell lung cancer.

A. Das, N. Iannotti, N. Gabrail, 2012, Clinical lung cancer.

A Randomized, Open-Label, Multicenter, Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared with Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemia Vera

C. Harrison, J. Gotlib, N. Gabrail, 2019, Blood.

A phase 1 dose-escalation study of the oral selective inhibitor of nuclear export (SINE) KPT-330 (selinexor) in patients (pts) with relapsed/refractory acute myeloid leukemia (AML).

I. Flinn, R. Garzon, D. DeAngelo, 2014 .

Efficacy of Oral Decitabine/Cedazuridine (ASTX727) in the CMML Subgroup from the Ascertain Phase 3 Study

B. Leber, H. Deeg, H. Kantarjian, 2021, Blood.

Abstract LB-194: First-in-human Phase I study of the CD40 agonist mAb CDX-1140 and in combination with CDX-301 (rhFLT3L) in patients with advanced cancers: Interim results

L. Vitale, N. Bhardwaj, M. O'Hara, 2019, Immunology.

Interim results from PX-171-006, a phase (Ph) II multicenter dose-expansion study of carfilzomib (CFZ), lenalidomide (LEN), and low-dose dexamethasone (loDex) in relapsed and/or refractory multiple myeloma (R/R MM).

D. Siegel, S. Singhal, P. Hari, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Multi-Center, Phase 1b Study to Assess the Safety, Pharmacokinetics and Efficacy of Subcutaneous Isatuximab Plus Pomalidomide and Dexamethasone, in Patients with Relapsed/Refractory Multiple Myeloma

A. Oriol, P. Moreau, E. Ocio, 2021, Blood.

Early efficacy evaluation of ORIN1001, a first in class IRE1 alpha inhibitor, in advanced solid tumors.

T. Pluard, A. Elias, N. Gabrail, 2023, Journal of Clinical Oncology.

A phase 1/2 trial of ORIN1001, a first-in-class IRE1 inhibitor, in patients with advanced solid tumors.

A. Hui, A. Elias, Wei Li, 2022, Journal of Clinical Oncology.

22P EMB-01: An EGFR-cMET bispecific antibody, in advanced/metastatic solid tumors phase I results

P. Jänne, N. Gabrail, Y. Wu, 2022, Annals of Oncology.

Pharmacokinetics (PK), tolerability, and efficacy of APF530 in patients receiving moderately (MEC) and highly (HEC) emetogenic chemotherapy: Phase II trial results.

N. Gabrail, M. Spaczyński, R. Yanagihara, 2013 .

Phase III study of sustained release granisetron (APF530) compared to palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV).

N. Gabrail, J. Grous, V. Charu, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Responses and durability of clinical benefit in non-small cell lung cancer treated with pegilodecakin in combination with anti-PD-1 inhibitors.

K. Papadopoulos, A. Naing, P. Munster, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

A randomized phase II trial of a vascular disrupting agent (VDA) fosbretabulin tromethamine (CA4P) with carboplatin (C), paclitaxel (P), and bevacizumab (B) in stage 3B/4 nonsquamous non-small cell lung cancer (NSCLC): Analysis of safety and activity of the FALCON trial.

F. Kabbinavar, N. Gabrail, E. Garon, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

a randomized Phase ii trial of the tumor vascular disrupting agent ca4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer

F. Kabbinavar, N. Gabrail, E. Garon, 2016 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Charles J. Vaske, Joe Y. Chang, Scott R. Presnell, 2016, Journal for ImmunoTherapy of Cancer.

Pharmacokinetics, safety, and efficacy of APF530 (extended-release granisetron) in patients receiving moderately or highly emetogenic chemotherapy: results of two Phase II trials

N. Gabrail, W. Cooper, E. O’Boyle, 2015, Cancer management and research.

Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia.

C. Hofmeister, S. Trudel, D. Reece, 2018, Blood.

Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification

E. Fadel, B. Bulik-Sullivan, N. Rizvi, 2018, Nature Biotechnology.

A Phase II Randomized Dose-Ranging Study of the JAK2-Selective Inhibitor SAR302503 in Patients with Intermediate-2 or High-Risk Primary Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF, or Post-Essential Thrombocythemia (ET) MF.

M. Talpaz, A. Tefferi, C. Jamieson, 2012 .

Open‐label, Phase 2 study of roxadustat for the treatment of anemia in patients receiving chemotherapy for non‐myeloid malignancies

N. Gabrail, J. Glaspy, D. Henry, 2023, American journal of hematology.

A Phase 2 Clinical Trial of AP23573, an mTOR Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies.

J. Dipersio, W. Stock, F. Giles, 2005 .

Carfilzomib: High Single Agent Response Rate with Minimal Neuropathy Even In High-Risk Patients

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2010 .

Dose-escalation study of carfilzomib (CFZ) plus lenalidomide (LEN) plus low-dose dexamethasone (Dex) (CRd) in relapsed/refractory multiple myeloma (R/R MM).

Michael L. Wang, S. Singhal, R. Orlowski, 2010 .

Oprozomib (OPZ) and Dexamethasone (DEX) in Patients (Pts) With Relapsed and/or Refractory Multiple Myeloma (RRMM): Updated Results From a Phase 1b/2, Multicenter, Open-Label Study

P. Richardson, P. Hari, P. Voorhees, 2015 .